The patient population in Phase II trials is typically more homogeneous compared to Phase I. Patients are usually selected based on specific inclusion criteria such as tumor type, stage of cancer, and prior treatments. This helps in ensuring that the results are more reliable and can provide clearer insights into the treatment’s effects.
